Phase 3
N=831
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Genital Neoplasms, Female · Fallopian Tube Neoplasms · Ovarian Neoplasms · Pelvic Neoplasms · Peritoneal Neoplasms
Bottom Line
View on ClinicalTrials.gov: NCT00191646 ↗Enrolled (actual)
831
Serious AEs
15.8%
Results posted
Sep 2010
Primary outcome: Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Gemcitabine (Drug); Paclitaxel (Drug); Carboplatin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Eli Lilly and Company
- Primary completion
- Aug 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression Free Survival (PFS) |
20.0; 22.2 | 0.199 |
| SECONDARY Proportion of Participants With Response (Response Rate) |
0.676; 0.711; 0.357; 0.303 | 0.771 |
| SECONDARY Time to Treatment Failure |
13.0; 13.1 | 0.621 |
| SECONDARY Overall Survival |
43.8; 57.3 | 0.013 sig |
Summary
This is a phase III randomized study comparing induction treatments of Gemcitabine and Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for patients that do not have any evidence of disease after completion of six cycles of induction therapy. Patients with disease after induction therapy will crossover to receive single agent therapy.
Eligibility Criteria
Key Inclusion Criteria
- Patients with a histologic diagnosis of primary peritoneal carcinoma, epithelial ovarian carcinoma or fallopian tube carcinoma Stage IC, II, III or IV.
- All patients must have had surgery for fallopian, ovarian or peritoneal carcinoma to establish the diagnosis and have tissue available for histologic evaluation and confirmation of organ of origin.
- Patients must be enrolled no more than twelve weeks postoperatively.
- Patients must be willing to receive their chemotherapy drugs intravenously, as intraperitoneal therapy is not part of this trial.
Key Exclusion Criteria
- Patients with a current diagnosis of epithelial ovarian tumor of low malignant potential (Borderline carcinomas) are not eligible.
- Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
- Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded
- With the exception of non-melanoma skin cancer and other specific malignancies patients who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy are excluded.
Data sourced from ClinicalTrials.gov (NCT00191646). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.